Dec. 7 at 4:33 AM
$ALT For those new here, PermaPumpers on this board have zero concept of the current state of
$ALT.
A fun argument they make is that the "Placebo arm abnormally performed well".
What they are failing to realize is what everyone else (BP, FDA, SEC, MMs, WS, etc.) sees;
$ALT's Pemvi failed to show improvement in Fibrosis without worsening of MASH.
Period. They ran the trial, the got the results, the results PROVED Pemvi didn't work for the Primary Endpoint (hence the 60% drop). For fun,
$ALT highlights that their Placebo dose did better for Fibrosis Improvement than
$ETNB and
$MDGL drug arms. Folks, I can't make this up. Look below.
That was
$ALT's make or break. Even the biggest pumpers now admitted it then.
$ALT failed. They go to the FDA with 50% of their primary endpoints for MASH P2b as FAILED.
If you have questions, ask. The Bull volume here wants you to forget the facts and reality so they can fool you to buy (to cover their losses).
Cheers!
